Equities

Quanterix Corp

QTRX:NMQ

Quanterix Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)16.88
  • Today's Change0.39 / 2.37%
  • Shares traded83.88k
  • 1 Year change+37.57%
  • Beta1.5132
Data delayed at least 15 minutes, as of May 02 2024 16:51 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.

  • Revenue in USD (TTM)122.37m
  • Net income in USD-32.33m
  • Incorporated2007
  • Employees441.00
  • Location
    Quanterix Corp900 Middlesex TurnpikeBILLERICA 01821United StatesUSA
  • Phone+1 (617) 301-9400
  • Fax+1 (302) 655-5049
  • Websitehttps://www.quanterix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Seer Inc16.66m-86.28m137.32m147.00--0.3434--8.24-1.35-1.350.26096.170.03611.792.43113,340.10-18.67-16.65-19.21-17.0951.05---517.84-756.7124.66--0.00--7.54--7.20--112.67--
Geospace Technologies Corp143.43m24.98m158.21m681.006.361.083.861.101.871.8710.7610.990.9383.764.35210,619.7016.34-5.1018.55-5.5444.2028.7017.42-8.963.79--0.00--39.5010.45153.40--11.01--
Harvard Bioscience, Inc.112.25m-3.42m165.87m391.00--2.2746.291.48-0.0803-0.08032.631.680.79411.816.84287,084.40-2.42-3.29-2.93-3.8958.8656.67-3.04-4.570.91640.44850.3335---0.9573-1.4564.11--18.10--
Northern Technologies International Corp82.70m3.66m166.87m86.0046.932.4424.402.020.37720.37728.617.250.95373.765.27961,669.605.886.297.447.7137.0133.216.167.421.86--0.052453.377.759.21-53.95-16.8734.3913.30
Virtra Inc38.04m8.40m178.53m112.0021.004.1919.134.690.76530.76533.473.840.61631.032.78339,672.8013.617.6917.169.7070.0959.0622.0911.122.32--0.1587--34.4216.04329.6259.3430.96--
908 Devices Inc.50.23m-36.40m186.93m230.00--1.12--3.72-1.13-1.131.565.090.22551.815.28218,387.00-16.34-14.16-18.03-15.3550.4153.02-72.47-64.257.04--0.00--7.2117.89-8.45--22.98--
FARO Technologies Inc358.83m-56.58m358.33m1.24k--1.33--0.9986-3.00-3.0018.9714.160.73384.583.94288,681.40-11.57-7.48-14.92-9.4945.9851.08-15.77-10.702.00-10.200.2131--3.78-2.33-111.46--1.61--
Mesa Laboratories Inc212.87m948.00k594.32m698.00629.101.4716.842.790.17510.175139.5474.700.30312.385.43304,977.100.1350.65350.14380.702961.0260.100.44531.971.860.26040.3663100.9618.8517.90-50.29--10.180.00
Quanterix Corp122.37m-32.33m630.69m441.00--1.81--5.15-0.8587-0.85873.269.130.28482.645.51277,478.50-7.53-15.96-8.19-17.6657.7352.79-26.42-53.799.26--0.00--15.9626.6066.56--20.07--
Standard Biotools Inc106.34m-74.66m962.31m534.00------9.05-0.9437-0.94371.342.030.29812.665.76199,138.60-20.93-28.17-26.63-33.6047.4451.58-70.21-74.851.26-13.800.2801--8.57-1.2060.73--50.06--
CTS Corp550.42m60.53m1.46bn4.08k24.752.7716.312.641.921.9217.4317.090.7395.886.49134,874.308.134.489.465.3334.6834.7111.005.862.67--0.113617.23-6.213.191.615.56-12.350.00
Data as of May 02 2024. Currency figures normalised to Quanterix Corp's reporting currency: US Dollar USD

Institutional shareholders

37.50%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20232.76m7.26%
Millennium Management LLCas of 31 Dec 20232.21m5.81%
The Vanguard Group, Inc.as of 31 Dec 20231.99m5.23%
Lord, Abbett & Co. LLCas of 31 Dec 20231.43m3.76%
Portolan Capital Management LLCas of 31 Dec 20231.30m3.41%
Gilder, Gagnon, Howe & Co. LLCas of 31 Dec 20231.20m3.16%
Dimensional Fund Advisors LPas of 31 Dec 2023974.11k2.56%
Ashford Capital Management, Inc.as of 31 Dec 2023831.89k2.19%
SSgA Funds Management, Inc.as of 31 Dec 2023809.05k2.13%
Geode Capital Management LLCas of 31 Dec 2023763.85k2.01%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.